CM
IMCR icon

Crestline Management’s Immunocore IMCR Stock Holding History

Crestline Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,960
Closed -$736K – 309
2024
Q4 		$736K Buy
+24,960
New +$789K 0.02% 471

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Crestline Management's IMCR Position: Q1 2025 in Review

Crestline Management sold out of Immunocore (IMCR) in Q1 2025, closing a stake of 24,960 shares — an estimated $736K sold.

Crestline Management first reported a position in IMCR in Q4 2024 and held it in 1 quarter. The position peaked at $736K in Q4 2024. 116 funds tracked by Wall St. Rank hold IMCR as of Q1 2025.

  • Crestline Management reported no remaining Immunocore position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 24,960 Immunocore shares in Q1 2025, an estimated $736K.
  • Crestline Management first reported a position in Immunocore in Q4 2024 and held it in 1 quarter.
  • Crestline Management's Immunocore position peaked at $736K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Immunocore as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.